Pharmaceuticals News and Research

RSS

FDA declines to grant Levulan PDT Orphan Designation: DUSA Pharmaceuticals

DUSA Pharmaceuticals, Inc. reported today that on the afternoon of August 5, 2010 the U.S. Food and Drug Administration notified DUSA that it has not granted Orphan Drug Designation for the use of Levulan (aminolevulinic acid HCl) Photodynamic Therapy for the prevention of cutaneous squamous cell carcinomas in patients who have a proven history of multiple localized cutaneous SCCs over a 12 month period.

7 Aug 2010

OncoGenex reports net income in second-quarter 2010 against loss last year

OncoGenex Pharmaceuticals, Inc. today reported unaudited financial results for the three and six months ended June 30, 2010 and reviewed the Company's highlights for the second quarter of 2010.

7 Aug 2010

AVANIR Pharmaceuticals reports net loss of $5.7M for third-quarter fiscal 2010

AVANIR Pharmaceuticals, Inc. today reported unaudited financial results for the three and nine months ended June 30, 2010.

7 Aug 2010

JumpStart Ventures announces investment commitment of $250,000 in ChanRx

JumpStart Ventures, which invests in and partners with innovative, early-stage companies in Northeast Ohio, announced an investment commitment of $250,000 in drug development company ChanRx. The two-year-old company is developing a pharmaceutical compound to treat atrial fibrillation, a heart condition that affects two million Americans, with 200,000 new cases being diagnosed each year.

6 Aug 2010

Accelrys revenues decline 2% to $19.8 million in second quarter

Accelrys, Inc. today reported financial results for the fiscal quarter ended June 30, 2010. Revenue for the quarter ended June 30, 2010 decreased 2% to $19.8 million from $20.1 million for the same quarter of the previous year.

6 Aug 2010

Threshold Pharmaceuticals reports net loss of $0.3M for second-quarter 2010

Threshold Pharmaceuticals, Inc., today reported financial results for the second quarter ended June 30, 2010.

6 Aug 2010

Cornerstone Pharmaceuticals includes Mary Crowley Research Centers in CPI-613 clinical trials

Cornerstone Pharmaceuticals, Inc. today announced the addition of Mary Crowley Cancer Research Centers to its roster of sites for its ongoing Phase I/II clinical trials of its first-in-class anti-cancer agent, CPI-613. Cornerstone is a leader in the discovery and development of cancer therapies that capitalize upon and disrupt the unique metabolic processes of cancer cells.

6 Aug 2010

V-101 shows safety profile in treating erythema of rosacea: Clinical study

Vicept Therapeutics, Inc., a privately held specialty biopharmaceutical company, announced positive results from a pharmacodynamic and pharmacokinetic clinical trial of the Company's lead product V-101, a topical cream under investigation for the treatment of erythema in patients with rosacea.

6 Aug 2010

Fidaxomicin, CDA1/CDB1 effective for treating CDI : Report

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, in first- and second-line treatment of Clostridium difficile infection, nearly 70 percent of surveyed infectious disease specialists and internists will use Optimer's fidaxomicin and nearly half will use Medarex/Merck's CDA1 and CDB1, one year after the launch of these agents. The lower recurrent/relapse rate associated with fidaxomicin and CDA1/CDB1 is the most influential attribute surveyed clinicians cite in their decisions to prescribe these emerging agents for CDI.

6 Aug 2010

Alnylam publishes research findings of Sort1 gene role in cardiovascular disease development

Alnylam Pharmaceuticals, Inc. a leading RNAi therapeutics company, announced today the publication of new research findings in the journal Nature describing the discovery and validation of the role of the gene Sort1 in the development of cardiovascular disease, including myocardial infarction (MI). This work was done with collaborators at University of Pennsylvania (UPenn) School of Medicine, Massachusetts General Hospital (MGH), and the Broad Institute. The collaborative effort combined genome-wide association studies (GWAS) and RNAi technology to identify and validate novel genes as targets for new therapies for heart disease.

6 Aug 2010

Vyvanse Capsules CII demonstrates significant improvement in adults with ADHD: Phase 3b study

Shire plc, the global specialty biopharmaceutical company, today announced that a Phase 3b study published in Behavioral and Brain Functions found adults with Attention Deficit Hyperactivity Disorder who took once-daily Vyvanse (lisdexamfetamine dimesylate) Capsules CII demonstrated significant improvement in attention.

6 Aug 2010

VWR International signs agreement to acquire scientific distribution businesses of EBOS Group

VWR International, LLC, a leading global laboratory supply and distribution company, announced today that it has signed an agreement to acquire the scientific distribution businesses of EBOS Group Limited, subject to customary closing conditions. The parties anticipate completion of the transaction on or about September 1, 2010.

6 Aug 2010

Helmsley Charitable Trust awards $3.15M grant to support UofL James Graham Brown Cancer Center

The University of Louisville has received a $3.15 million grant from the Leona M. and Harry B. Helmsley Charitable Trust to support the UofL James Graham Brown Cancer Center and cancer research taking place in Owensboro. The grant will be matched with state "Bucks for Brains" funding to bring more than $4.5 million to the Owensboro Cancer Research Program.

6 Aug 2010

TEMPO study recommends early administration of Azilect in PD patients

Teva Pharmaceutical Industries Ltd. and H. Lundbeck A/S (Lundbeck) today announced newly published long-term data on Azilect(rasagiline tablets) from the TEMPO study and its open-label extension. The findings confirm the long-term efficacy, safety and tolerability of Azilect® in patients with Parkinson's disease (PD) and further demonstrate the benefits obtained with early treatment initiation. The data was published in the June 2010 issue of the International Journal of Neuroscience.

6 Aug 2010

Patheon, Dendreon announce signing of technology transfer agreement

Patheon, a global provider of drug development and manufacturing services to the international pharmaceutical industry, announced today that it has signed a technology transfer agreement with Dendreon Corporation for commercial supply of proprietary density gradient solutions required during the PROVENGE (sipuleucel-T) manufacturing process.

6 Aug 2010

Nanosphere reports net loss of $13.8M for second-quarter 2010

Nanosphere, Inc., a leader in the development and commercialization of advanced molecular diagnostics systems, today reported financial results for the second quarter ended June 30, 2010.

6 Aug 2010

Impax Laboratories to collaborate with Perrigo to develop, commercialize two extended topical products

Impax Laboratories, Inc. today announced that it will collaborate with Perrigo Company with respect to the development and commercialization of two extended topical drug products. The products and terms of the agreement were not disclosed.

6 Aug 2010

Agendia inaugurates new clinical genomics laboratory

Agendia, a world leader in molecular cancer diagnostics, today announced the inauguration of a new state-of-the-art clinical genomics laboratory in Irvine, CA. Previously, Agendia's offices and laboratory were located in Huntington Beach, CA. The new laboratory will further increase capacity to support Agendia's strong commercial expansion in the U.S. market, as well as the use of multiple Agendia tests in clinical research. MammaPrint, the company's lead product and the only FDA-cleared breast cancer recurrence test, is reimbursed by an increasing number of payers, covering some 100 million lives today.

6 Aug 2010

WaferGen launches SmartChip System for discovery, validation of biomarkers

WaferGen Biosystems, Inc., a leading developer of state-of-the-art genomic analysis systems, today announced it has launched the breakthrough WaferGen SmartChip Real-Time PCR System, the next-generation Real-Time PCR system for discovery and validation of biomarkers, or gene expression patterns, on a single platform. The SmartChip System is designed to provide accurate, highly sensitive and high-throughput gene expression profiling capabilities to researchers, clinicians and pharmaceutical companies.

6 Aug 2010

Sanofi-aventis receives FDA approval for new Taxotere Injection Concentrate formulation

Sanofi-aventis U.S. announced today that the U.S. Food and Drug Administration (FDA) has approved a new one-vial formulation of its chemotherapeutic agent Taxotere® (docetaxel) Injection Concentrate. The 1-vial Taxotere is anticipated to become available to cancer treatment clinics and hospitals nationwide in the fall in both 80 mg and 20 mg dosages.

5 Aug 2010